Dimitriou, F., Orloff, M. M., Koch Hein, E. C., Cheng, P. F., Hughes, I. F., Simeone, E., Montazeri, K., Grover, P., Mehmi, I., Gerard, C. L., Gaudy-Marqueste, C., Grob, J.-J., Michielin, O., Hamid, O., Long, G. V., Sullivan, R., Kapiteijn, E., Johnson, D. B., Ascierto, P. A., … Dummer, R. (2025). Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. European Journal of Cancer, 214, 115161. https://doi.org/10.1016/j.ejca.2024.115161

Conway, K., Edmiston, S. N., Vondras, A., Reiner, A., Corcoran, D. L., Shen, R., Parrish, E. A., Hao, H., Lin, L., Kenney, J. M., Ilelaboye, G., Kostrzewa, C. E., Kuan, P. F., Busam, K. J., Lezcano, C., Lee, T. K., Hernando, E., Googe, P. B., Ollila, D. W., … Rainka, M. (2024). DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. JCO Precision Oncology, 8. https://doi.org/10.1200/po-24-00375

Baraban, E. G., Gru, A., Guo, R., Elias, R., Pallavajjala, A., Dudley, J. C., & Gross, J. M. (2024). Neurofibroma-like Desmoplastic Melanoma. American Journal of Surgical Pathology. https://doi.org/10.1097/pas.0000000000002327

Ma, K. L., Mitchell, T. C., Dougher, M., Sharon, C. E., Tortorello, G. N., Elder, D. E., Morgan, E. E., Gimotty, P. A., Huang, A. C., Amaravadi, R. K., Schuchter, L. M., Flowers, A., Miura, J. T., Karakousis, G. C., & Xu, X. (2024). Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival. Clinical Cancer Research, 30(21), 4987–4994. https://doi.org/10.1158/1078-0432.ccr-23-3775

Ventin, M., Cattaneo, G., Arya, S., Jia, J., Gelmi, M. C., Sun, Y., Maggs, L., Ksander, B. R., Verdijk, R. M., Boland, G. M., Jenkins, R. W., Haq, R., Jager, M. J., Wang, X., Ryeom, S., & Ferrone, C. R. (2024). Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting. Clinical Cancer Research, 30(15), 3243–3258. https://doi.org/10.1158/1078-0432.ccr-24-0071

Kinslow, C. J., DeStephano, D. M., Neugut, A. I., Taparra, K., Horowitz, D. P., Yu, J. B., & Cheng, S. K. (2024). Site-specific patterns of early-stage cancer diagnosis during the COVID-19 pandemic. JNCI Cancer Spectrum, 8(3). https://doi.org/10.1093/jncics/pkae022

Wu, L. W., Tao, J. J., McDonnell, D., & Izar, B. (2024). Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition. Melanoma Research, 34(4), 382–385. https://doi.org/10.1097/cmr.0000000000000974

Yuan, H., Kehm, R. D., Daaboul, J. M., Lloyd, S. E., McDonald, J. A., Mu, L., Tehranifar, P., Zhang, K., Terry, M. B., & Yang, W. (2024). Cancer incidence trends in New York State and associations with common population-level exposures 2010–2018: an ecological study. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-024-56634-w

Mendelson, K., Martin, T. C., Nguyen, C. B., Hsu, M., Xu, J., Lang, C. C. V., Dummer, R., Saenger, Y., Messina, J. L., Sondak, V. K., Desman, G., Hasson, D., Bernstein, E., Parsons, R. E., & Celebi, J. T. (2024). Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation. JCI Insight. https://doi.org/10.1172/jci.insight.166611

Leuzzi, G., Vasciaveo, A., Taglialatela, A., Chen, X., Firestone, T. M., Hickman, A. R., Mao, W., Thakar, T., Vaitsiankova, A., Huang, J.-W., Cuella-Martin, R., Hayward, S. B., Kesner, J. S., Ghasemzadeh, A., Nambiar, T. S., Ho, P., Rialdi, A., Hebrard, M., Li, Y., … Ciccia, A. (2024). SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell, 187(4), 861-881.e32. https://doi.org/10.1016/j.cell.2024.01.008

Fahmy, L. M., Schreidah, C. M., McDonnell, D. E., Carvajal, R. D., Magro, C. M., & Geskin, L. J. (2024). Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma. Dermatology Online Journal, 29(6). https://doi.org/10.5070/d329662993

Neo, S. Y., Oliveira, M. M. S., Tong, L., Chen, Y., Chen, Z., Cismas, S., Burduli, N., Malmerfelt, A., Teo, J. K. H., Lam, K.-P., Alici, E., Girnita, L., Wagner, A. K., Westerberg, L. S., & Lundqvist, A. (2024). Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease. Journal of Experimental & Clinical Cancer Research, 43(1). https://doi.org/10.1186/s13046-023-02917-5

Ko, B., Tao, K., Brennan, L., Rakhade, S., Chan, C. X., Moone, J.-Y., Zhu, R., Sher, A., Wang, S., Bracero, Y., Fullerton, B., McLellan, B., Geskin, L. J., & Saenger, Y. M. (2024). Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients. Melanoma Research, 34(2), 134–141. https://doi.org/10.1097/cmr.0000000000000945

Lin, C.-C., Garralda, E., Schöffski, P., Hong, D. S., Siu, L. L., Martin, M., Maur, M., Hui, R., Soo, R. A., Chiu, J., Zhang, T., Ma, B., Kyi, C., Tan, D. S., Cassier, P. A., Sarantopoulos, J., Weickhardt, A., Carvajal, R. D., Spratlin, J., … De Braud, F. (2023). A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. OncoImmunology, 13(1). https://doi.org/10.1080/2162402x.2023.2290787

Melms, J. C., Ho, P., Rogava, M., & Izar, B. (2023). From patient tissue correlates to molecular mechanisms of cancer immune evasion: the emerging role of CD58 and PD-L1 co-regulation via CMTM6. Genes & Immunity, 25(1), 82–84. https://doi.org/10.1038/s41435-023-00224-9

Wei, A. Z., Chen, L. N., Orloff, M., Ariyan, C. E., Asgari, M., Barker, C. A., Buchbinder, E., Chandra, S., Couts, K., Frumovitz, M. M., Futreal, A., Gershenwald, J. E., Hanna, E. Y., Izar, B., LeBlanc, A. K., Leitao, M. M., Lipson, E. J., Liu, D., McCarter, M., … Carvajal, R. D. (2023). Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA). Pigment Cell & Melanoma Research, 36(6), 542–556. Portico. https://doi.org/10.1111/pcmr.13139

Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., Luke, J. J., Mitchell, T. C., Mooradian, M. J., Rubin, K. M., Salama, A. K., Shirai, K., Taube, J. M., Tawbi, H. A., Tolley, J. K., … Sullivan, R. J. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal for ImmunoTherapy of Cancer, 11(10), e006947. https://doi.org/10.1136/jitc-2023-006947

Liu, Y., Mullangi, S., Debono, D., Chen, X., Pham, T., Fisch, M. J., Gordon, A. S., & Hershman, D. L. (2023). Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid Tumors. JCO Oncology Practice, 19(9), 731–740. https://doi.org/10.1200/op.23.00199

Ho, P., Melms, J. C., Rogava, M., Frangieh, C. J., Poźniak, J., Shah, S. B., Walsh, Z., Kyrysyuk, O., Amin, A. D., Caprio, L., Fullerton, B. T., Soni, R. K., Ager, C. R., Biermann, J., Wang, Y., Khosravi-Maharlooei, M., Zanetti, G., Mu, M., Fatima, H., … Izar, B. (2023). The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. Cancer Cell, 41(7), 1207-1221.e12. https://doi.org/10.1016/j.ccell.2023.05.014

Hsu, C.-C., Fidler, T. P., Kanter, J. E., Kothari, V., Kramer, F., Tang, J., Tall, A. R., & Bornfeldt, K. E. (2023). Hematopoietic NLRP3 and AIM2 Inflammasomes Promote Diabetes-Accelerated Atherosclerosis, but Increased Necrosis Is Independent of Pyroptosis. Diabetes, 72(7), 999–1011. https://doi.org/10.2337/db22-0962

Park, H.-R., Shiva, A., Cummings, P., Kim, S., Kim, S., Lee, E., Leong, A., Chowdhury, S., Shawber, C., Carvajal, R., Thurston, G., An, J.-Y., Lund, A. W., Yang, H. W., & Kim, M. (2023). Angiopoietin-2–Dependent Spatial Vascular Destabilization Promotes T-cell Exclusion and Limits Immunotherapy in Melanoma. Cancer Research, 83(12), 1968–1983. https://doi.org/10.1158/0008-5472.can-22-2838

Kim, S., Carvajal, R., Kim, M., & Yang, H. W. (2023). Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma. Cell Reports, 42(6), 112570. https://doi.org/10.1016/j.celrep.2023.112570

Ambrosini, G., Natale, C. A., Musi, E., Garyantes, T., & Schwartz, G. K. (2023). The GPER Agonist LNS8801 Induces Mitotic Arrest and Apoptosis in Uveal Melanoma Cells. Cancer Research Communications, 3(4), 540–547. https://doi.org/10.1158/2767-9764.crc-22-0399

Orlow, I., Sadeghi, K. D., Edmiston, S. N., Kenney, J. M., Lezcano, C., Wilmott, J. S., Cust, A. E., Scolyer, R. A., Mann, G. J., Lee, T. K., Burke, H., Jakrot, V., Shang, P., Ferguson, P. M., Boyce, T. W., Ko, J. S., Ngo, P., Funchain, P., … Rees, J. R. (2023). InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma. PLOS ONE, 18(4), e0269324. https://doi.org/10.1371/journal.pone.0269324

Carvajal, R. D., Sacco, J. J., Jager, M. J., Eschelman, D. J., Olofsson Bagge, R., Harbour, J. W., Chieng, N. D., Patel, S. P., Joshua, A. M., & Piperno-Neumann, S. (2023). Advances in the clinical management of uveal melanoma. Nature Reviews Clinical Oncology, 20(2), 99–115. https://doi.org/10.1038/s41571-022-00714-1

Gartrell, R. D., Enzler, T., Kim, P. S., Fullerton, B. T., Fazlollahi, L., Chen, A. X., Minns, H. E., Perni, S., Weisberg, S. P., Rizk, E. M., Wang, S., Oh, E. J., Guo, X. V., Chiuzan, C., Manji, G. A., Bates, S. E., Chabot, J., Schrope, B., Kluger, M., … Saenger, Y. M. (2022). Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. OncoImmunology, 11(1). https://doi.org/10.1080/2162402x.2022.2066767

Tanagala, K. K. K., Morin-Baxter, J., Carvajal, R., Cheema, M., Dubey, S., Nakagawa, H., Yoon, A., Cheng, Y.-S. L., Taylor, A., Nickerson, J., Mintz, A., & Momen-Heravi, F. (2022). SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response. Journal for ImmunoTherapy of Cancer, 10(12), e005088. https://doi.org/10.1136/jitc-2022-005088

Wei, A. Z., Maniar, A. B., & Carvajal, R. D. (2022). New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma. Cancer Gene Therapy, 29(12), 1819–1826. https://doi.org/10.1038/s41417-022-00443-8

Dercle, L., Ammari, S., Roblin, E., Bigorgne, A., Champiat, S., Taihi, L., Plaian, A., Hans, S., Lakiss, S., Tselikas, L., Rouanne, M., Deutsch, E., Schwartz, L. H., Gönen, M., Flynn, J., Massard, C., Soria, J.-C., Robert, C., & Marabelle, A. (2022). High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. European Journal of Cancer, 177, 80–93. https://doi.org/10.1016/j.ejca.2022.08.034

Ascierto, P. A., Agarwala, S. S., Blank, C., Caracò, C., Carvajal, R. D., Ernstoff, M. S., Ferrone, S., Fox, B. A., Gajewski, T. F., Garbe, C., Grob, J.-J., Hamid, O., Krogsgaard, M., Lo, R. S., Lund, A. W., Madonna, G., Michielin, O., Neyns, B., Osman, I., … Thurin, M. (2022). Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy). Journal of Translational Medicine, 20(1). https://doi.org/10.1186/s12967-022-03592-4

Capaccione, K. M., Valiplackal, J. P., Huang, A., Roa, T., Fruauff, A., Liou, C., Kim, E., Khurana, S., Maher, M., Ma, H., Ngyuen, P., Mak, S., Dumeer, S., Lala, S., D’souza, B., Laifer-Narin, S., Desperito, E., Ruzal-Shapiro, C., & Salvatore, M. M. (2022). Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review. Academic Radiology, 29(12), 1869–1884. https://doi.org/10.1016/j.acra.2022.03.007

Jung, S., Armstrong, E., Wei, A. Z., Ye, F., Lee, A., Carlino, M. S., Sullivan, R. J., Carvajal, R. D., Shoushtari, A. N., & Johnson, D. B. (2022). Clinical and genomic correlates of imatinib response in melanomas with KIT alterations. British Journal of Cancer, 127(9), 1726–1732. https://doi.org/10.1038/s41416-022-01942-z

Luo, L., Shen, R., Arora, A., Orlow, I., Busam, K. J., Lezcano, C., Lee, T. K., Hernando, E., Gorlov, I., Amos, C., Ernstoff, M. S., Seshan, V. E., Cust, A. E., Wilmott, J., Scolyer, R. A., Mann, G., Nagore, E., Funchain, P., … Ko, J. (2022). Landscape of mutations in early stage primary cutaneous melanoma: An InterMEL study. Pigment Cell & Melanoma Research, 35(6), 605–612. Portico. https://doi.org/10.1111/pcmr.13058

Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., Hernandez-Aya, L., Nathan, P., Hamid, O., Piulats, J. M., Rioth, M., Johnson, D. B., Luke, J. J., Espinosa, E., Leyvraz, S., Collins, L., Goodall, H. M., Ranade, K., Holland, C., Abdullah, S. E., … Sato, T. (2022). Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nature Medicine, 28(11), 2364–2373. https://doi.org/10.1038/s41591-022-02015-7

Karras, P., Bordeu, I., Pozniak, J., Nowosad, A., Pazzi, C., Van Raemdonck, N., Landeloos, E., Van Herck, Y., Pedri, D., Bervoets, G., Makhzami, S., Khoo, J. H., Pavie, B., Lamote, J., Marin-Bejar, O., Dewaele, M., Liang, H., Zhang, X., Hua, Y., … Marine, J.-C. (2022). A cellular hierarchy in melanoma uncouples growth and metastasis. Nature, 610(7930), 190–198. https://doi.org/10.1038/s41586-022-05242-7

Dimitriou, F., Namikawa, K., Reijers, I. L. M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K. C., … Long, G. V. (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33(9), 968–980. https://doi.org/10.1016/j.annonc.2022.06.004

Alvarez-Breckenridge, C., Markson, S. C., Stocking, J. H., Nayyar, N., Lastrapes, M., Strickland, M. R., Kim, A. E., de Sauvage, M., Dahal, A., Larson, J. M., Mora, J. L., Navia, A. W., Klein, R. H., Kuter, B. M., Gill, C. M., Bertalan, M., Shaw, B., Kaplan, A., Subramanian, M., … Carter, S. L. (2022). Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Cancer Immunology Research, 10(8), 996–1012. https://doi.org/10.1158/2326-6066.cir-21-0870

Gartrell, R. D., Blake, Z., Rizk, E. M., Perez-Lorenzo, R., Weisberg, S. P., Simoes, I., Esancy, C., Fu, Y., Davari, D. R., Barker, L., Finkel, G., Mondal, M., Minns, H. E., Wang, S. W., Fullerton, B. T., Lozano, F., Chiuzan, C., Horst, B., & Saenger, Y. M. (2022). Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma. Cancer Immunology, Immunotherapy, 71(8), 1837–1849. https://doi.org/10.1007/s00262-021-03088-y

Biermann, J., Melms, J. C., Amin, A. D., Wang, Y., Caprio, L. A., Karz, A., Tagore, S., Barrera, I., Ibarra-Arellano, M. A., Andreatta, M., Fullerton, B. T., Gretarsson, K. H., Sahu, V., Mangipudy, V. S., Nguyen, T. T. T., Nair, A., Rogava, M., Ho, P., Koch, P. D., … Izar, B. (2022). Dissecting the treatment-naive ecosystem of human melanoma brain metastasis. Cell, 185(14), 2591-2608.e30. https://doi.org/10.1016/j.cell.2022.06.007

Carvajal, R. D., Nathan, P., Sacco, J. J., Orloff, M., Hernandez-Aya, L. F., Yang, J., Luke, J. J., Butler, M. O., Stanhope, S., Collins, L., McAlpine, C., Holland, C., Abdullah, S. E., & Sato, T. (2022). Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of Clinical Oncology, 40(17), 1939–1948. https://doi.org/10.1200/jco.21.01805

Verginadis, I. I., Avgousti, H., Monslow, J., Skoufos, G., Chinga, F., Kim, K., Leli, N. M., Karagounis, I. V., Bell, B. I., Velalopoulou, A., Salinas, C. S., Wu, V. S., Li, Y., Ye, J., Scott, D. A., Osterman, A. L., Sengupta, A., Weljie, A., Huang, M., … Koumenis, C. (2022). A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression. Nature Cell Biology, 24(6), 940–953. https://doi.org/10.1038/s41556-022-00918-8

Dieng, M., Lord, S. J., Turner, R. M., Nieweg, O. E., Menzies, A. M., Saw, R. P. M., Einstein, A. J., Emmett, L., Thompson, J. F., Lo, S. N., & Morton, R. L. (2022). The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma. Annals of Surgical Oncology, 29(5), 2871–2881. https://doi.org/10.1245/s10434-021-11231-3

Ambrosini, G., Rai, A. J., Carvajal, R. D., & Schwartz, G. K. (2022). Uveal Melanoma Exosomes Induce a Prometastatic Microenvironment through Macrophage Migration Inhibitory Factor. Molecular Cancer Research, 20(4), 661–669. https://doi.org/10.1158/1541-7786.mcr-21-0526

Dieng, M., Turner, R. M., Lord, S. J., Einstein, A. J., Menzies, A. M., Saw, R. P. M., Nieweg, O. E., Thompson, J. F., & Morton, R. L. (2022). Cost-Effectiveness of PET/CT Surveillance Schedules to Detect Distant Recurrence of Resected Stage III Melanoma. International Journal of Environmental Research and Public Health, 19(4), 2331. https://doi.org/10.3390/ijerph19042331

Liu, A. W., Wei, A. Z., Maniar, A. B., & Carvajal, R. D. (2022). Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. Expert Opinion on Biological Therapy, 22(8), 997–1004. https://doi.org/10.1080/14712598.2022.2031970

Palmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022). Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors. Clinical Cancer Research, 28(2), 368–377. https://doi.org/10.1158/1078-0432.ccr-21-2275

Dercle, L., Zhao, B., Gönen, M., Moskowitz, C. S., Firas, A., Beylergil, V., Connors, D. E., Yang, H., Lu, L., Fojo, T., Carvajal, R., Karovic, S., Maitland, M. L., Goldmacher, G. V., Oxnard, G. R., Postow, M. A., & Schwartz, L. H. (2022). Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis. JAMA Oncology, 8(3), 385. https://doi.org/10.1001/jamaoncol.2021.6818